Abstract
BackgroundPatients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have